Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;53(10):4185-92.
doi: 10.1128/AAC.00225-09. Epub 2009 Jul 20.

New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289

Tanja Wenzler  1 , David W Boykin, Mohamed A Ismail, James Edwin Hall, Richard R Tidwell, Reto Brun
Affiliations

New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289

Tanja Wenzler et al. Antimicrob Agents Chemother. 2009 Oct.

Abstract

African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829 (CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypanosoma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain (AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Dimethoxyamidine prodrugs and their active parent diamidines.
FIG. 2.
FIG. 2.
Monoamidoxime/monomethoxyamidine metabolites (M1s) and diamidoxime metabolites (M2s).
See this image and copyright information in PMC

References

    1. Anbazhagan, M., J. Y. Saulter, J. E. Hall, and D. W. Boykin. 2003. Synthesis of metabolites of the prodrug 2,5-bis(4-O-methoxyamidinophenyl)furan. Heterocycles 60:1133-1145.
    1. Ansede, J. H., M. Anbazhagan, R. Brun, J. D. Easterbrook, J. E. Hall, and D. W. Boykin. 2004. O-Alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. 47:4335-4338. - PubMed
    1. Ansede, J. H., R. D. Voyksner, M. A. Ismail, D. W. Boykin, R. R. Tidwell, and J. E. Hall. 2005. In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica 35:211-226. - PubMed
    1. Balasegaram, M., H. Young, F. Chappuis, G. Priotto, M.-E. Raguenaud, and F. Checchi. 2009. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Trans. R. Soc. Trop. Med. Hyg. 103:280-290. - PubMed
    1. Balmer, O., and A. Caccone. 2008. Multiple-strain infections of Trypanosoma brucei across Africa. Acta Trop. 107:275-279. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources